All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Described herein are devices for delivering therapeutic fluids, and more particularly small, disposable, portable infusion devices and methods that can be used to transcutaneously deliver fluids safely and simply to a patient.
During drug delivery, it is often desirable to bypass the digestive system of a patient to avoid degradation of the drug's active ingredients that can be caused by the catalytic enzymes in the digestive tract and liver. Delivery of a drug other than by way of the intestines is known as parenteral delivery. Parenteral delivery of drugs in liquid form is often desired to enhance the effect of the substance being delivered, insuring that the unaltered medicine reaches its intended site at a significant concentration. Moreover, undesired side effects associated with other routes of delivery, such as systemic toxicity, can potentially be avoided by parenteral delivery. Further, many medicines are only available in liquid form, and/or the liquid may have desirable characteristics that cannot be achieved with solid or pill form. Delivery of liquid medicines may best be accomplished by infusing directly into the cardiovascular system via veins or arteries, into the subcutaneous tissue, or directly into organs, tumors, cavities, bones, or other site-specific locations within the body.
Parenteral delivery of liquid medicines into the body is often accomplished by administering bolus injections using a needle and reservoir or continuously by gravity driven dispensers or transdermal patch technologies. Bolus injections often imperfectly match the clinical needs of the patient and usually require larger individual doses than are desired at the specific time they are given. Continuous delivery of medicine through gravity feed systems compromise the patient's mobility and lifestyle and limit the therapy to simplistic flow rates and profiles. Transdermal patches have special requirements of the medicine being delivered, particularly as it relates to the molecular structure, and similar to gravity feed systems, the control of the drug administration is severely limited.
Ambulatory infusion pumps have been developed for delivering liquid medicaments to a patient. These infusion devices have the ability to offer sophisticated fluid delivery profiles that can provide bolus delivery, continuous infusion, and variable flow rate delivery. Ambulatory infusion pumps, however, can be problematic, as the user is generally forced to choose between a soft delivery cannula, which tends to have high initial failure rates and is prone to kinking, or a steel needle set, which has a lower initial failure rate but is associated with increased pain and shortened time of use. Additionally, the challenge with current infusion sets is that the 90-degree (i.e., rigid cannula) infusion sets, which are easiest to insert, are also associated with the highest rates of failure, partially due to needle breakage and/or fluid leaking out of the relatively short insertion path. Further, infusion sets with a soft cannula, however, tend to be harder to insert and/or are associated with increased apprehension/intimidation.
Moreover, a necessary and important step in preparing an infusion set for use is filling the tubing with liquid medicament, such as insulin to be delivered to a person with diabetes. This is often done by attaching the infusion set tubing to either the insulin pump reservoir or the insulin pump reservoir adaptor (e.g., a device that holds the reservoir into the pump). The pump is then programmed to fill the tubing with insulin. This is not an automatic process. The user is typically either asked to hold down a button until the tubing is filled or to program an amount believed to be sufficient to fill the tubing. The user is instructed not to move on to another step until they observe insulin drops exiting the distal end of the tubing to infusion site connection or the distal end of the infusion cannula. The observation confirms that the tubing has been filled.
Tube filling carries two risk cases. The first risk case is when the user attempts to fill the tube and makes the mistake of connecting the tube to an infusion set that has already been inserted into their body. This would prevent the user from knowing when the tube had been completely filled and would result in any excess insulin delivered in an attempt to fill the tube to be delivered to the pump user, resulting in an over delivery. Over delivery carries with it a significant risk of hypoglycemia (low blood glucose levels). The second risk case is incomplete filling of the tubing. Failure to completely fill the tubing can lead to under delivery of insulin. This in turn can lead to hyperglycemia (elevated glucose levels). The amount of missed insulin (10 to 15 units) can be approximately 25 to 50% of a typical pump user's daily dose (˜42 units) but could exceed the total daily dose of a pump user with higher than typical insulin sensitivity. In many cases, the missed insulin associated with a non-filled or partially filled tube causes a significant health risk to the pump user. Filling the tubing is not an easy task, especially for those with any macular degeneration, as is often associated with diabetes progression.
Accordingly, an ambulatory infusion pump set that is efficient, safe, effective, easy to insert into a patient, and easy/safe to fill is desired.
In general, in one embodiment, a device for delivering fluid to a patient includes a housing assembly, a subcutaneous infusion cannula assembly extending from the housing, an insertion mechanism, and a fluid connection port. The insertion mechanism is configured to extend the infusion cannula in a helical path from the housing assembly. The fluid connection port is configured to connect the device to a source of delivery fluid.
This and other embodiments can include one or more of the following features. The infusion cannula can have a pre-set curved shape. The device can further include a sharp inner stylet configured to extend through the infusion cannula. The sharp inner stylet can have a pre-set curved shape. The insertion mechanism can further include mechanical features to define or limit the depth of extension of the infusion cannula from the housing assembly. The insertion mechanism can further include a rotational drive mechanism configured to rotate the infusion cannula as the cannula is extended from the housing assembly. The rotational drive mechanism can be a spring. The housing can include an adhesive on at least one surface thereof configured to attach the device to skin of the patient. The subcutaneous infusion cannula can be flexible. The cannula can include an outer tube and an inner reinforcement coil. The cannula can include two or more fluid exit holes at or near the distal end thereof. The insertion mechanism can include an automatic retraction mechanism for moving the stylet from the advanced position to the retracted position on completion of the insertion cycle. The housing assembly can contain a releasable fluid interconnect assembly to connect the subcutaneous cannula assembly to the source of fluid.
In some embodiments, a system for delivering fluid to a user transcutaneously includes a subcutaneous infusion cannula base assembly, a cannula inserter assembly and a fluid connection assembly. The subcutaneous infusion cannula base assembly is configured to be located on the user's skin. The cannula inserter assembly is coupled to the cannula base assembly and is configured to drive an infusion cannula through the user's skin in a nominally helical trajectory. The fluid connection assembly is configured to fluidically connect the cannula base assembly to a source of delivery fluid.
In some of the above embodiments, the inserter assembly is removably coupled to the cannula base assembly. The system may further comprise a sharp inner stylet configured to extend through the infusion cannula. The sharp inner stylet may have a pre-set curved shape. In some embodiments, the cannula base assembly includes an adhesive on at least one surface thereof configured to attach the cannula base assembly to the user's skin. In some embodiments, the subcutaneous infusion cannula is flexible. The cannula may include an outer tube and an inner reinforcement coil. In some embodiments, the cannula includes two or more fluid exit holes at or near the distal end thereof.
In some embodiments, the inserter assembly includes an automatic retraction mechanism configured to move the stylet from an advanced position to a retracted position after completion of a cannula insertion cycle. The inserter assembly may also include an automatic release mechanism configured to decouple the inserter assembly from the cannula base assembly after completion of a stylet retraction cycle. The inserter assembly may be configured to automatically perform the cannula insertion cycle, the stylet retraction cycle and a release cycle in succession after a single trigger event without further interaction from the user. In some embodiments, the inserter assembly includes a single drive spring configured to supply all energy required to drive the cannula insertion cycle, the stylet retraction cycle and the release cycle. The system may further comprise packaging for enclosing at least the inserter assembly before use. The inserter assembly may include at least one drive spring, and the inserter assembly may be configured to automatically charge the drive spring as the packaging is being opened.
In some embodiments, the fluid connection assembly of the infusion system includes tubing and an element or assembly that changes color when the tubing has been primed with fluid. The fluid connection assembly may include a releasable fluid interconnect assembly configured to releasably connect the cannula base assembly to the source of delivery fluid, and the source of delivery fluid may be external to the cannula base assembly. The releasable fluid interconnect assembly may include a needle and a septum, and the fluid interconnect assembly may be configured to insert an end of the needle through the septum after a cannula stylet is withdrawn from the septum.
In some embodiments, a system for delivering fluid to a user transcutaneously includes a subcutaneous infusion cannula base assembly, a cannula inserter assembly and a fluid connection assembly. The cannula base assembly is configured to be located on the user's skin and includes an infusion cannula having a central lumen therethrough. The cannula includes a reinforcing coil extending along a portion of the central lumen. The coil has at least two different pitches along its length. The cannula inserter assembly is coupled to the cannula base assembly and includes a sharp stylet configured to pass through the central lumen of the cannula. The inserter assembly is configured to drive the stylet and infusion cannula together through the user's skin without a needle placed over the cannula. The fluid connection assembly is configured to fluidically connect the cannula base assembly to a source of delivery fluid.
In some of the above embodiments, the reinforcing coil has a first section with a first coil pitch and a second section with a second coil pitch, the first section being located more distally in the cannula than the second section. In these embodiments, the first coil pitch is greater than the second coil pitch. In some embodiments, the first coil pitch is an open pitch and the second coil pitch is a closed pitch. In some embodiments, the first section includes a plurality of holes though a side wall of the cannula. The inserter assembly may be configured to drive the stylet and infusion cannula together through the user's skin at a 90 degree angle. The inserter assembly may be configured to drive the stylet and infusion cannula together through the user's skin at an angle of less than 45 degrees.
In some embodiments, a system for delivering fluid to a user transcutaneously includes a subcutaneous infusion cannula base assembly, a cannula inserter assembly and a fluid connection assembly. The cannula base assembly is configured to be located on the user's skin and includes an infusion cannula formed from a polyether block amide thermoplastic elastomer having a central lumen therethrough. The cannula has a nominal outside diameter no greater than 0.56 mm. The cannula includes a reinforcing coil extending along a portion of the central lumen. The reinforcing coil has a nominal inside diameter and a nominal outside diameter. The nominal outside diameter is the same as a nominal inside diameter of the central lumen it resides in. The reinforcing coil has a first section with a first coil pitch and a second section with a second coil pitch. The first coil section is located more distally in the cannula than the second section. The first coil pitch is an open pitch and the second coil pitch is a closed pitch. The first section includes a plurality of holes though a side wall of the cannula. The cannula includes a distalmost section having an outer taper of between 10 and 30 degrees and no reinforcing coil located in the distalmost section. A portion of the cannula is siliconized to reduce insertion force. The cannula inserter assembly is coupled to the cannula base assembly and includes a sharp stylet configured to pass through the central lumen of the cannula. The stylet has a nominal outside diameter that is the same as the nominal inside diameter of the reinforcing coil. The stylet has a sharpened distal tip that extends from the distalmost section of the cannula. The inserter assembly is configured to drive the stylet and cannula together through the user's skin without a needle placed over the cannula. The fluid connection assembly is configured to fluidically connect the cannula base assembly to a source of delivery fluid.
The novel features of the disclosure are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:
Described herein are subcutaneous infusion devices that promote wearability, increase wear-life, and effectively deliver fluid transcutaneously. The in-dwelling infusion devices may include a multi-orifice soft cannula and a user-depth controlled curved insertion cannula that provides for a spiral or helical insertion path through the tissue.
As shown in
In some embodiments, the hollow curved cannula 102 can be a 24 Ga catheter (0.56 m outer diameter) made of a polymer-coated stainless steel coil. In other embodiments, the cannula 102 can be made entirely of metal, e.g., stainless steel. The curved shape can, for example, be heat set into the cannula 102. The curved shape of the cannula 102 can, for example, have a radius of curvature of between 0.5 inches and 1.25 inches. Further, the curved shape of the cannula 102 can have a pitch, for example, of between 10 mm and 30 mm. In some embodiments, the cannula 102 can end in a sharpened tip. The hollow curved cannula 102 can further include a series of perforations, including one or more fluid exit holes 111 along the length thereof in a variety of patterns. Further, the hollow curved cannula 102, due to its curvature, can be inserted at a 30°-60° angle relative to the plane of the skin surface in a spiral or helical path that accommodates target insertion depths ranging from 6 to 10 mm. Further, in some embodiments, the curve of the hollow curved cannula can provide for a 1-3 cm diameter insertion path.
A similar infusion device 200 is shown in
Another similar infusion device 300 is shown in
As shown in
Use of the insertion device 433 with the infusion device 300 is described with respect to
In some embodiments, the user can preselect the insertion depth using the knob 435 prior to inserting the cannula 302. As shown in
In some embodiments, to remove the cannula 302 from the patient, the cannula 302 can be retracted back into the body 301. For example, as shown in
Another infusion device 1000 that is similar to infusion device 300 is shown in
A package 980 holding a combined insertion device 933 and infusion set 900 is shown in
The exterior packaging 999 of the insertion device 933 advantageously facilitates or promotes a specific user operational sequence that encourage proper use of the product and help ensure patient safety. That is, the insertion device 933 is packaged so as to encourage the tubing of the infusion device to be filled with fluid before inserting the set. As shown in
The connection for tube to the pump is in an easy to reach location that presents itself to the use upon opening the packaging 999, thereby advantageously encouraging the user to grab it first when unpacking the set. Further, the tubing-to-pump connection and the portion of the tubing immediately attached to it can be positioned/held within the external packaging 999 so that the tubing to pump connection can be removed from the packaging 999 without removing the bulk of the tubing (i.e., the first foot or so of tubing comes lose with the tubing to pump connection but the rest of the tubing stays in place until intentionally removed). This allows the user to fill the tube without removing the bulk of it from the packaging 999 and without exposing the rest of the infusion device 900 until after the tubing is filled. In concert with positioning the pump connection at an easily accessible location, the tube-to-infusion set hub connection can be positioned in a less accessible location. This discourages the user from grabbing that end first and helps ensure the flow of fill tubing before inserting the infusion set.
In some embodiments, the packing 999 can further include a material thereon that changes color when droplets of insulin or diluent contact it. This advantageously helps the user know that the tubing has been filled. In some embodiments, the color changing material can be located so that when the package is resting on a flat surface, gravity directs any droplets exiting the distal end of the tubing towards the material. In an alternative embodiment, the distal portion of the tube to infusion set hub connector can contain the material that changes color when in contact with insulin or diluent.
Close-ups of an exemplary curved cannula 602 for use with any of the infusion devices described herein are shown in
Referring to
In some embodiments, the cannula can be replaced with a spirally or helically inserted body analyte sensor. For example, the body analyte sensor can be a wire assembly including chemistry components.
Further, in some embodiments, the cannula, once inserted in a spiral or helical fashion, can function as a spring member to provide three-dimensional strain relief. Thus, for example, the infusion set adhesively attached to the dermis can freely move without transferring moment energy to the cannula.
In some embodiments, the cannula is soft and semi-rigid and is coated with a lubricating element, such as a liquid, a conformal coating applied by dipping and drying, or a coating applied by gas or vapor deposition.
In some embodiments, the cannula can include an anti-inflammatory agent, an anti-biotic agent, and/or an anti-clotting agent thereon.
Referring to
In some embodiments, the reinforcing coil can have a fixed pitch from the proximal to the distal ends. In other embodiments, the reinforcing coil can have a variable pitch from the proximal to distal end. For example, the pitch can vary from 1:1 to 1:n over a defined region and at a defined distance from either the distal or the proximal end. The reinforcing coil can be made of stainless steel or of an engineering polymer. Further, the reinforcing coil can be a round wire or a flat wire. In some embodiments, the reinforcing coil can be injection molded. In some embodiments, the cannula can have a fixed durometer from the proximal to the distal end. In other embodiments, the cannula can have a varied durometer from the proximal to the distal end.
Although the depth control mechanism is described above with respect to an external insertion device, the depth control mechanism can also be used as part of an internal insertion mechanism, such as that described with respect to device 200.
In embodiments where a separate external insertion device (such as device 433) is used, the insertion device can be either reusable or single-use. For single use designs, the insertion device can include the cannula therein. In such an embodiment, a locking mechanism may be used that prevents the cannula from being released again.
In some embodiments, the fluid connections described herein can be attachable and detachable from the fluid source. The fluid connection can include, for example, a standard Luer lock or Minimed Paradigm connection point for connection to the pump and/or fluid reservoir. In some embodiments, the connection can include a valve, such as a septum valve, that ensures that the connection remains in a closed state until initiation of an external fluid supply physical connection. The connection can be reusable, can have only one correct insertion direction, can include features to prevent accidental disconnect, and/or can allow for connection to commercially available infusion tube sets. In some embodiments, various lengths of pump tubing may be provided (e.g. 23, 32 and 43 inch long tubing) to accommodate patient comfort and convenience.
In some embodiments, the devices described herein can have a visual indicator to show that the cannula has been fully inserted. For example, there can be a window in the hollow body to allow the user to see the indicator. The indicator can be, for example, a visual color change or a visual indicator symbol. Similarly, the devices described herein can have a visual indicator to show that the cannula has been fully retracted. This visual indicator can also be, for example, a window in the hollow body and can include a color change or visual indicator symbol For example, referring to
Advantageously, the infusion delivery device and system described herein can be simple to use yet provide enhanced fluid delivery capabilities. For example, the system can allow for controlled delivery of fluid to different and precise depths, thereby permitting delivery to areas with both thin and thick layers of fat or tissue. Further, the spiral or helical insertion path of the cannula can advantageously help reduce tissue trauma from insertion relative to devices that insert the cannula at 90 degrees relative to the surface of the skin. Insertion along a long spiral or helical path also helps prevent leakage of delivered fluid, which can otherwise occur along short (e.g., 90 degree) insertion paths. The described system can therefore reduce thrombus formation, inflammation, infiltration of the wound, and encapsulation.
Advantageously, the infusion delivery devices described herein can also have a small footprint, small packaging, and/or a small profile about the skin while providing for an angled insertion path (i.e., non-90 degree insertion). For example, the height of the device (i.e., distance it extends about the skin) can be less than 0.5 inches, such as less than 0.4 inches or less than 0.3 inches. The device body can have a diameter of less than 1.5 inches, such as less than 1.2 inches, such as less than 1.0 inches. Further, the adhesive attachment patch can have a diameter of less than 1.5 inches, such as less than 1.4 inches.
Referring now to
Referring to
In this exemplary embodiment, a Tyvek label 426 is used during the manufacture of system 400 to cover aperture 427 in lid 404. Aperture 427 is one of several apertures used to allow sterilization gas (such as Ethylene Oxide) to freely circulate within the closed package during product sterilization. After sterilization, label 426 is applied to lid 404 to ensure infusion system 400 remains sterile. A larger label 428 is then used to cover the top of lid 404.
Underneath removable inserter assembly 406 (not shown in
Referring to
Referring to
Referring to
Referring to
When inserter assembly 406 is assembled, base 514 is adhered to the top side of adhesive patch 492. Rotor 510 is rotatably retained on the center hub of base 514. Septum 512 is located in a curved circumferential channel through a radially extending wing of rotor 510. Cannula 508 is located on stylet 506 such that a short tip portion of stylet 506 extends from the distal end of cannula 508 and a proximal portion of stylet 506 including a 90 degree bend extends from the proximal end of cannula 508. The distal end of stylet 506 and cannula 508 extend from the curved circumferential channel in a clockwise direction (when viewed from above). The proximal end of cannula 508 terminates inside the curved channel in a sealed manner with the channel, while the proximal end of stylet continues through the channel and septum 512, and extends out the opposite end of the channel in the counter-clockwise direction.
Throughout the insertion process and later use of the infusion set, the adhesive patch 492, base 514, rotor 510, septum 512 and cannula 508 remain together as a unit referred to as the base assembly 526. Base assembly 526 is first releasably attached to the rest of inserter assembly 406 by way of bottom rotor 500. Once the distal end of cannula 508 is inserted through a user's skin and stylet 506 is retracted, base assembly 526 is released from inserter assembly 406 and becomes a separate unit that remains on the user's skin.
Inserter assembly 406 may be provided to a user in a sterilized and sealed state inside closed jar 402 and lid 404 (as shown by
As previously described, once lid 404 is unscrewed from jar 402, pump connector 414 located at one end of tubing 410 (shown in
Still referring to
When bottom fork 504 reaches the end of its clockwise travel (marking the end of the stylet and cannula insertion cycle), tabs on the top of middle fork 496 force arms in bottom housing 488 to disengage bottom rotor 500 from its locked position, initiating the start of the stylet retraction cycle. At this point, the top of torsion spring 498 has been wound about 360 degrees in counter-clockwise direction by the charging cycle and unwound about 120 degree in the clockwise direction by the stylet and cannula insertion cycle. This leaves enough stored energy in spring 498 to drive the bottom rotor 500 about 240 degrees in the counter-clockwise direction during the stylet retraction cycle. Bottom rotor 500 drives top rotor 502 which in turn drives stylet 506 about 240 degrees in the counter-clockwise direction, which removes stylet 506 from cannula 508 and withdraws stylet 506 out of sight into the inserter, as will be subsequently described in more detail. Once bottom rotor 500 reaches the end of its counter-clockwise travel, locking features on bottom rotor 500 release base 514 so that inserter assembly 406 can be removed from the user, leaving adhesive patch 492, base 514, rotor 510 and cannula 508 intact on the user.
As disclosed above, once release buttons 494 are pressed, the aforementioned components cooperate to automatically insert cannula 508 and stylet 506 through the skin in a clockwise direction, then retract stylet 506 in a counter-clockwise direction, and then release the base assembly from the inserter assembly without further interaction from the user. A single spring 498 provides all of the energy required for this automatic insertion and retraction process. Before, during and after this process, the user is never able to see or touch stylet 506 or cannula 508, providing further safety and comfort to the user. In other embodiments, only one release button 494 may be provided, or if multiple release buttons are provided only one needs to be pressed to automatically activate the insertion, retraction and release cycles. This may be referred to as a single “trigger event”, regardless of how many buttons need to be pushed.
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
In the state shown in
Referring to
Referring to
Referring to
Referring to
In some embodiments, inserter assembly 406 has a maximum diameter no greater than 2.25 inches and a height no greater than 1.5 inches. In some embodiments, when connector assembly 412 is coupled to base 514, the combined assembly has a maximum diameter no greater than 1.25 inches and a height above the user's skin no greater than 0.3 inches.
Referring to
In the exemplary embodiment disclosed herein, cannula 508 is formed from a polyether block amide (PEBA) thermoplastic elastomer, such as a PEBA sold under the tradename of Pebax® by Arkema Inc. headquartered in King of Prussia, PA. Applicants have found that using a Pebax® material having a durometer of 72 D, in combination with other features disclosed herein, provides greatly improved cannula performance over lower durometers such as 63 D. In this embodiment, cannula 508 has a length L of 24.8 mm and an outside diameter of 0.56 mm. Except for a short region at the distal tip of cannula 508 (as shown in
In this exemplary embodiment, three holes 550 are formed in cannula 508, each through one wall of the Pebax® only and having a diameter of 0.15 mm. Holes 550 may be placed 2 mm apart from each other and no more than 2 mm from the distal tip of cannula 508. The three holes 550 may be placed evenly around the circumference of cannula 508 such that they are 120 degrees apart. With this axial and circumferential spacing, holes 550 form a helical pattern. In other embodiments (not shown), fewer, more or no holes may be provided, they may have a different diameter or diameters, and various alternative spacing patterns may be used.
As depicted in
Referring to
Referring to
Referring to
Referring to
Referring to
In order to achieve the favorable results shown in
Referring to
In some embodiments, it is desirable to insert cannula 508 into the skin such that its distal tip resides between 4 and 9 mm below the surface (measured perpendicularly from the surface of the skin.) Because of the slenderness and softness of cannula 508 and stylet 506, and the varying densities of tissue anatomies below the skin, the cannula and stylet are not likely to travel in a perfectly helical path. The exemplary infusion system 400 disclosed herein is designed to insert a 14 mm length of cannula 508 at an angle of 30 degrees below the skin with a nominal helical radius of 7.15 mm such that the distal tip resides 7 mm below the surface, as shown in the middle line of the table in
The systems described herein can advantageously allow transcutaneous placement of a soft cannula safely and automatically. The systems advantageously also do not require the disposal of a sharp, contaminated needle, since the stylet can be fully retracted back into the housing. The systems described herein are designed to be single use disposable units, but in other embodiments portions of the system such as the inserter may be made to be multi-use.
The disclosed infusion devices can be used, for example, for insulin delivery and thus may help to reduce the burden of managing diabetes by: (1) extending the wear duration from three to seven or more days, matching insulin pump cartridge and CGM sensor lifetime, (2) preserving infusion sites by minimizing tissue trauma, scar formation and lipodystrophy, (3) reducing the frequency of set failure and unexpected hyperglycemia, (4) providing more predictable insulin response by enhancing absorption, and/or (5) improving blood glucose control with a lower incidence of hypoglycemia.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the FIGS. is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present disclosure.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
In general, any of the apparatuses and methods described herein should be understood to be inclusive, but all or a sub-set of the components and/or steps may alternatively be exclusive, and may be expressed as “consisting of” or alternatively “consisting essentially of” the various components, steps, sub-components or sub-steps.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the disclosure as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the disclosure as it is set forth in the claims.
The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” or “disclosure” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.
This application is a continuation of U.S. patent application Ser. No. 16/433,884, filed Jun. 6, 2019, titled “HELICAL INSERTION INFUSION DEVICE,” now U.S. Publication No. US-2019-0282753-A1, which is a continuation of U.S. patent application Ser. No. 15/943,517, filed Apr. 2, 2018, titled “HELICAL INSERTION INFUSION DEVICE,” now U.S. Pat. No. 10,413,658, which claims the benefit of U.S. Provisional Patent Application No. 62/480,190, filed Mar. 31, 2017, and titled “SPIRAL INSERTION INFUSION DEVICE,” and U.S. Provisional Patent Application No. 62/517,825, filed Jun. 9, 2017 and titled “SPIRAL INSERTION DEVICE,” each of which is here incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4498843 | Schneider et al. | Feb 1985 | A |
4703756 | Gough et al. | Nov 1987 | A |
4755173 | Konopka | Jul 1988 | A |
4777953 | Ash et al. | Oct 1988 | A |
4952207 | Lemieux | Aug 1990 | A |
5002054 | Ash et al. | Mar 1991 | A |
5176662 | Bartholomew et al. | Jan 1993 | A |
5425723 | Wang | Jun 1995 | A |
5545152 | Funderburk et al. | Aug 1996 | A |
5584831 | McKay | Dec 1996 | A |
5704926 | Sutton | Jan 1998 | A |
5848996 | Eldor | Dec 1998 | A |
5869774 | Backlund et al. | Feb 1999 | A |
5879367 | Latterell et al. | Mar 1999 | A |
5899891 | Racz | May 1999 | A |
5919369 | Ash | Jul 1999 | A |
5925018 | Ungerstedt | Jul 1999 | A |
5947953 | Ash et al. | Sep 1999 | A |
5995860 | Sun et al. | Nov 1999 | A |
6017361 | Mikus et al. | Jan 2000 | A |
6030358 | Odland | Feb 2000 | A |
6042561 | Ash et al. | Mar 2000 | A |
6042576 | De Vries | Mar 2000 | A |
6049727 | Crothall | Apr 2000 | A |
6056718 | Funderburk et al. | May 2000 | A |
6122536 | Sun et al. | Sep 2000 | A |
6179816 | Mattola et al. | Jan 2001 | B1 |
6261272 | Gross et al. | Jul 2001 | B1 |
6302866 | Marggi | Oct 2001 | B1 |
6304766 | Colvin, Jr. | Oct 2001 | B1 |
6471689 | Joseph et al. | Oct 2002 | B1 |
6488663 | Steg | Dec 2002 | B1 |
6537241 | Odland | Mar 2003 | B1 |
6572542 | Houben et al. | Jun 2003 | B1 |
6572586 | Wojcik | Jun 2003 | B1 |
6585695 | Adair et al. | Jul 2003 | B1 |
6618603 | Varalli et al. | Sep 2003 | B2 |
6702857 | Brauker et al. | Mar 2004 | B2 |
6736797 | Larsen et al. | May 2004 | B1 |
6749589 | Douglas et al. | Jun 2004 | B1 |
6770030 | Schaupp et al. | Aug 2004 | B1 |
6800451 | Daniloff et al. | Oct 2004 | B2 |
6805683 | Johansson | Oct 2004 | B1 |
6830562 | Mogensen | Dec 2004 | B2 |
6855136 | Dorros et al. | Feb 2005 | B2 |
6862534 | Sterling et al. | Mar 2005 | B2 |
6929618 | Johansson | Aug 2005 | B1 |
6940590 | Colvin, Jr. et al. | Sep 2005 | B2 |
6989891 | Braig et al. | Jan 2006 | B2 |
7009180 | Sterling et al. | Mar 2006 | B2 |
7022071 | Schaupp et al. | Apr 2006 | B2 |
7052483 | Wojcik | May 2006 | B2 |
7070580 | Nielsen | Jul 2006 | B2 |
7128727 | Flaherty et al. | Oct 2006 | B2 |
7147623 | Mathiasen | Dec 2006 | B2 |
7157723 | Colvin, Jr. et al. | Jan 2007 | B2 |
7211068 | Douglas | May 2007 | B2 |
7235350 | Schulman et al. | Jun 2007 | B2 |
7248912 | Gough et al. | Jul 2007 | B2 |
7255687 | Huang et al. | Aug 2007 | B2 |
7309325 | Mulier et al. | Dec 2007 | B2 |
7336984 | Gough et al. | Feb 2008 | B2 |
7364592 | Carr-Brendel et al. | Apr 2008 | B2 |
7588558 | Sage, Jr. et al. | Sep 2009 | B2 |
7593108 | Sterling et al. | Sep 2009 | B2 |
7613491 | Boock et al. | Nov 2009 | B2 |
7621395 | Mogensen et al. | Nov 2009 | B2 |
7637918 | Dant | Dec 2009 | B2 |
7651845 | Doyle et al. | Jan 2010 | B2 |
7666172 | Atil | Feb 2010 | B2 |
7686787 | Moberg et al. | Mar 2010 | B2 |
7699808 | Marrs et al. | Apr 2010 | B2 |
7722537 | Sterling et al. | May 2010 | B2 |
7744570 | Fangrow, Jr. | Jun 2010 | B2 |
7800078 | Colvin, Jr. et al. | Sep 2010 | B2 |
7822450 | Colvin, Jr. et al. | Oct 2010 | B2 |
7867199 | Mogensen et al. | Jan 2011 | B2 |
7867200 | Mogensen et al. | Jan 2011 | B2 |
7871456 | Gough et al. | Jan 2011 | B2 |
7875008 | Chong et al. | Jan 2011 | B2 |
7894870 | Lucisano et al. | Feb 2011 | B1 |
7905877 | Jimenez et al. | Mar 2011 | B1 |
7931621 | Cross et al. | Apr 2011 | B2 |
7935092 | Odland et al. | May 2011 | B1 |
7939332 | Colvin, Jr. | May 2011 | B2 |
7951357 | Gross et al. | May 2011 | B2 |
7985199 | Komerup et al. | Jul 2011 | B2 |
8012126 | Tipsmark et al. | Sep 2011 | B2 |
8043229 | Mulvihill et al. | Oct 2011 | B2 |
8062250 | Mogensen et al. | Nov 2011 | B2 |
8073548 | Colvin, Jr. et al. | Dec 2011 | B2 |
8114064 | Alferness et al. | Feb 2012 | B2 |
8143068 | Colvin, Jr. et al. | Mar 2012 | B2 |
8157773 | Tashjian | Apr 2012 | B2 |
8172805 | Mogensen et al. | May 2012 | B2 |
8204565 | Arnold et al. | Jun 2012 | B2 |
8206343 | Racz | Jun 2012 | B2 |
8229546 | Falkén et al. | Jul 2012 | B2 |
8273061 | McConnell et al. | Sep 2012 | B2 |
8273228 | Dall'Oglio et al. | Sep 2012 | B2 |
8303533 | Regittnig et al. | Nov 2012 | B2 |
8318193 | Ratner et al. | Nov 2012 | B2 |
8333734 | Zohmann | Dec 2012 | B2 |
8403911 | Adams et al. | Mar 2013 | B2 |
8415184 | Colvin et al. | Apr 2013 | B2 |
8502167 | Colvin, Jr. et al. | Aug 2013 | B2 |
8535537 | Feichtner et al. | Sep 2013 | B2 |
8562567 | Gundberg | Oct 2013 | B2 |
8604810 | Sheppard | Dec 2013 | B2 |
8608729 | Christenson | Dec 2013 | B2 |
8608922 | Papadimitrakopoulos et al. | Dec 2013 | B2 |
8647393 | Marshall et al. | Feb 2014 | B2 |
8708994 | Pettis et al. | Apr 2014 | B2 |
8827979 | Pesach et al. | Sep 2014 | B2 |
8945057 | Gym et al. | Feb 2015 | B2 |
8971981 | Yodfat et al. | Mar 2015 | B2 |
9084848 | Schiltges et al. | Jul 2015 | B2 |
9114208 | Smith et al. | Aug 2015 | B2 |
9131960 | Racz | Sep 2015 | B2 |
9180244 | Anderson et al. | Nov 2015 | B2 |
9192717 | Cote et al. | Nov 2015 | B2 |
9227013 | Lacy | Jan 2016 | B2 |
9375529 | Searle et al. | Jun 2016 | B2 |
9399094 | Krag et al. | Jul 2016 | B2 |
9463889 | Schmitz et al. | Oct 2016 | B2 |
9480792 | Constantineau et al. | Nov 2016 | B2 |
9522229 | Sonderegger et al. | Dec 2016 | B2 |
9579452 | Adair et al. | Feb 2017 | B2 |
9713674 | Carter et al. | Jul 2017 | B2 |
9782536 | Skutnik et al. | Oct 2017 | B2 |
9782538 | Cole et al. | Oct 2017 | B2 |
9821113 | Cole et al. | Nov 2017 | B2 |
9968742 | Antwerp et al. | May 2018 | B2 |
10076605 | Marbet et al. | Sep 2018 | B2 |
10080839 | Cole et al. | Sep 2018 | B2 |
10173007 | Hayter et al. | Jan 2019 | B2 |
10265483 | Cole et al. | Apr 2019 | B2 |
10413658 | Gillett et al. | Sep 2019 | B2 |
10420489 | Kovatchev et al. | Sep 2019 | B2 |
10434285 | Schoonmaker et al. | Oct 2019 | B2 |
10449296 | Kapas et al. | Oct 2019 | B2 |
10463787 | Shor et al. | Nov 2019 | B2 |
10675403 | Montalvo et al. | Jun 2020 | B2 |
10722653 | Kapas et al. | Jul 2020 | B2 |
10828418 | Constantineau et al. | Nov 2020 | B2 |
10943687 | Blomquist | Mar 2021 | B2 |
11273255 | Gillett et al. | Mar 2022 | B2 |
20020016614 | Klein et al. | Feb 2002 | A1 |
20020123740 | Flaherty et al. | Sep 2002 | A1 |
20040075198 | Schweikert et al. | Apr 2004 | A1 |
20040143216 | Douglas et al. | Jul 2004 | A1 |
20040158207 | Hunn et al. | Aug 2004 | A1 |
20040236290 | Zimmermann | Nov 2004 | A1 |
20050137525 | Wang et al. | Jun 2005 | A1 |
20050192558 | Bernard et al. | Sep 2005 | A1 |
20050273076 | Beasley | Dec 2005 | A1 |
20060100583 | Terzoli | May 2006 | A1 |
20060122536 | Haar et al. | Jun 2006 | A1 |
20060135941 | Porto et al. | Jun 2006 | A1 |
20060135981 | Lenker et al. | Jun 2006 | A1 |
20060211933 | Zimmermann et al. | Sep 2006 | A1 |
20070060834 | Odland et al. | Mar 2007 | A1 |
20070062251 | Anex | Mar 2007 | A1 |
20070282269 | Carter et al. | Dec 2007 | A1 |
20080091173 | Belley et al. | Apr 2008 | A1 |
20080108950 | Rioux et al. | May 2008 | A1 |
20080243085 | DeStefano | Oct 2008 | A1 |
20080269687 | Chong | Oct 2008 | A1 |
20080287877 | Gresham et al. | Nov 2008 | A1 |
20080319414 | Yodfat et al. | Dec 2008 | A1 |
20090048563 | Ethelfeld et al. | Feb 2009 | A1 |
20090069750 | Schraga | Mar 2009 | A1 |
20090099521 | Gravesen | Apr 2009 | A1 |
20090156926 | Messerly et al. | Jun 2009 | A1 |
20100063445 | Sternberg | Mar 2010 | A1 |
20100160749 | Gross et al. | Jun 2010 | A1 |
20100286714 | Gym et al. | Nov 2010 | A1 |
20100298830 | Browne et al. | Nov 2010 | A1 |
20100303772 | McMillan et al. | Dec 2010 | A1 |
20110099789 | Ewing et al. | May 2011 | A1 |
20120059320 | Maule et al. | Mar 2012 | A1 |
20120078226 | Latere Dwanisa et al. | Mar 2012 | A1 |
20120265034 | Wisniewski et al. | Oct 2012 | A1 |
20130126349 | Zhang | May 2013 | A1 |
20130245555 | Dirac et al. | Sep 2013 | A1 |
20130338630 | Agrawal et al. | Dec 2013 | A1 |
20140025039 | Rajendran et al. | Jan 2014 | A1 |
20140031793 | Constantineau et al. | Jan 2014 | A1 |
20140058353 | Politis et al. | Feb 2014 | A1 |
20140088555 | Li | Mar 2014 | A1 |
20140343538 | Lenker | Nov 2014 | A1 |
20150011970 | Kamen et al. | Jan 2015 | A1 |
20150051583 | Horvath et al. | Feb 2015 | A1 |
20150057611 | Bureau | Feb 2015 | A1 |
20150112302 | Chattaraj et al. | Apr 2015 | A1 |
20150165161 | Uber, III et al. | Jun 2015 | A1 |
20150182693 | Rosinko | Jul 2015 | A1 |
20150265767 | Varquez et al. | Sep 2015 | A1 |
20150283321 | Dang et al. | Oct 2015 | A1 |
20150290390 | Ring et al. | Oct 2015 | A1 |
20160106919 | Hayter et al. | Apr 2016 | A1 |
20160279325 | Searle et al. | Sep 2016 | A1 |
20160290390 | Ambroise et al. | Oct 2016 | A1 |
20170021096 | Cole et al. | Jan 2017 | A1 |
20170076068 | Dobbles et al. | Mar 2017 | A1 |
20170189614 | Mazlish et al. | Jul 2017 | A1 |
20180021508 | Destefano | Jan 2018 | A1 |
20180104411 | Chovanda et al. | Apr 2018 | A1 |
20180200412 | Dang et al. | Jul 2018 | A1 |
20180207356 | Joseph et al. | Jul 2018 | A1 |
20180220942 | El-Khatib et al. | Aug 2018 | A1 |
20180369479 | Hayler et al. | Dec 2018 | A1 |
20190053742 | Steil et al. | Feb 2019 | A1 |
20190099555 | Patek et al. | Apr 2019 | A1 |
20190175840 | Schabbach et al. | Jun 2019 | A1 |
20190224409 | Sonderegger | Jul 2019 | A1 |
20190388015 | Biomquist et al. | Dec 2019 | A1 |
20200147300 | Novak et al. | May 2020 | A1 |
20200222625 | Cabiri et al. | Jul 2020 | A1 |
20200246541 | Neftel et al. | Aug 2020 | A1 |
20200345929 | Ben-David et al. | Nov 2020 | A1 |
20210402084 | Coker et al. | Dec 2021 | A1 |
Number | Date | Country |
---|---|---|
2659005 | Apr 2014 | CA |
2950966 | Jul 2019 | CA |
100366305 | Feb 2008 | CN |
101027095 | Sep 2010 | CN |
1608420 | Nov 2006 | EP |
2004241 | Dec 2008 | EP |
1951340 | Aug 2009 | EP |
2193814 | Jun 2010 | EP |
2457606 | May 2012 | EP |
2099384 | Sep 2018 | EP |
2560727 | Feb 2019 | EP |
3459574 | Mar 2019 | EP |
2254622 | May 2019 | EP |
2259815 | Jun 2019 | EP |
2350895 | Jun 2019 | EP |
3698828 | Aug 2020 | EP |
3134150 | Feb 2021 | EP |
3576823 | Mar 2021 | EP |
WO96032981 | Oct 1996 | WO |
WO01034237 | May 2001 | WO |
WO2007140632 | Dec 2007 | WO |
WO2010084113 | Jul 2010 | WO |
WO2012073097 | Jun 2012 | WO |
WO2012118762 | Sep 2012 | WO |
WO 2017053572 | Mar 2017 | WO |
WO2017125817 | Jul 2017 | WO |
WO2018184012 | Oct 2018 | WO |
Entry |
---|
Bryant, J., Fluid dynamics—Equation of continuity and Bernoulli's principle; retrieved from the internet at http://www.physics.usyd.edu.au/˜jbryant/Fluids/Fluidslect4.pdf on Apr. 2, 2015; 37 pages. |
Calthorpe, N., The history of spinal needles: getting to the point; Anaesthesia; 59(12); pp. 1231-1241; Dec. 2004. |
Campolo et al., Protocols to compare infusion distribution of wound catheters; Med. Eng. Phys.; 34(3); pp. 326-332; Apr. 2012. |
Centers for Disease Control and Prevention (CDCP); National Diabetes Statistics Report, 2014—Estimates of Diabetes and Its Burden in the United States; U.S. Dept. of Health and Human Services, Atlanta, GA; 8 pgs.; 2014 (the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publication is not in issue). |
Cho et al., On-line near-infrared spectrometer to monitor urea removal in real time during hemodialysis; Appl. Spectrosc.; 62(8); pp. 866-872; Aug. 2008. |
Dziubla et al., Evaluation of porous networks of poly(2-hydroxyethyl methacrylate) as interfacial drug delivery devices; Biomaterials; 22(21); pp. 2893-2899; Nov. 2001. |
Edsberg et al., Insulin bolus given by sprinkler needle: effect on absorption and glycaemic response to a meal; Br. Med. J. Clin. Res. Ed.; 294(6584); pp. 1373-1376; May 30, 1987. |
Jockel et al., Insulin depot formation in subcutaneous tissue; J. Diabetes Sci. Technol.; 7(1); pp. 227-237; Jan. 2013. |
Miller et al., Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry; Diabetes Care; 38(6); pp. 971-978; Jun. 2015. |
Neithercott, T., Infusion Sets 2014—How to choose the kind of insulin delivery that's right for you; Diabetes Forecast® ; (downloaded from the internet at http://www.diabetesforecast.org/2014/Jan/infusion-sets-2014.html on Dec. 6, 2018); Dec. 2013; 2 pgs. |
Patel et al., Randomized trial of infusion set function: steel versus teflon; Diabetes Technol. and Ther.; 16(1); pp. 15-19; Jan. 2014. |
Pfutzner et al., Improved Insulin Absorption by Means of Standardized Injection Site Modulation Results in a Safer and More Efficient Prandial Insulin Treatment; A Review of the Existing Clinical Data; J. Diabetes Sci. Technol.; 9(1); pp. 116-122; Jan. 2015. |
Walsh et al., Insulin Pump and CGM Usage in the United States and Germany: Results of a Real-World Survey with 985 Subjects; J. Diabetes Sci. Technol.; 9(5); pp. 1103-1110; Sep. 2015. |
Wootten et al., Broadband 2.4 μm superluminescent GaIn—AsSb/AlGaAsSb quantum well diodes for optical sensing of biomolecules; Semicond. Sci. Technol. (Internet); 29(11); Nov. 2014 doi: 10.1088/0268-1242/29/11/115014; Avail. from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283575/. |
Oberg et al.; U.S. Appl. No. 17/446,271 entitled “Insulin infusion set,” filed Aug. 27, 2021. |
EP Application No. 18777919.4; Examination Report dated Jan. 19, 2023, 6 pages. |
Number | Date | Country | |
---|---|---|---|
20220370708 A1 | Nov 2022 | US |
Number | Date | Country | |
---|---|---|---|
62517825 | Jun 2017 | US | |
62480190 | Mar 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16433884 | Jun 2019 | US |
Child | 17650827 | US | |
Parent | 15943517 | Apr 2018 | US |
Child | 16433884 | US |